A cell-signaling pathway known as Wnt, which is commonly activated in cancers, causes membranes within a healthy cell to imprison an enzyme that is vital in degrading proteins, preventing the enzyme from doing its job, researchers at UCLA’s Jonsson Comprehensive Cancer Center have found.
The finding is important because sequestering the enzyme, glycogen synthase kinase 3, or GSK3, results in the stabilization of proteins in the cell, at least one of which is known to be a key player in cancer, said Dr. Edward De Robertis, senior author of the study and a Jonsson Cancer Center scientist. Degradation of old proteins is a necessary part of regular cellular maintenance.
Dr. Edward De Robertis
“Surprisingly, we found that the degradation of about 20 percent of proteins in the cell is triggered by the GSK3 enzyme,” said De Robertis, a Howard Hughes Medical Institute investigator. “That’s a great many proteins. And one of them, beta-catenin, is known to cause cancer. We also know that Wnt signaling is activated in about 85 percent of colorectal cancers and that other forms of cancer start with mutations that activate Wnt signaling. So this finding could have ramifications for potential new treatments for cancer.”
The study, conducted in collaboration with New York University cell biologist Dr. David D. Sabatini, is published in the Dec. 23 issue of the peer-reviewed journal Cell.
De Robertis said that Wnt signaling requires inhibition of GSK3 — but the enzyme-sequestration mechanism was not known until now. The enzyme becomes imprisoned inside membrane-bounded organelles known as multivesicular bodies, which are found within a cell’s cytoplasm.
“We knew these multivesicular bodies were involved in degradation of proteins, but that they had a role in how cells communicate with each other by switching on a signaling pathway was not known,” De Robertis said. “This finding raises the possibility that other signaling pathways could operate through this sequestration mechanism.”
When cells receive Wnt, it’s a signal for them to degrade their proteins more slowly, to keep them for a longer period of time because they’re needed to regulate certain cell functions, such as proliferation. Wnt signaling is very high, for example, in all stem cells and rises during the regeneration of most tissues, De Robertis said.
“Perhaps one of the functions of Wnt is to stabilize certain cell functions, and it may be that cancer needs higher protein stability than other cells, which is why increased Wnt signaling if found in so many cancers,” De Robertis said. “These findings may give us new therapeutic targets for preventing sequestrations inside these membranes, which would decrease Wnt signaling.”
De Robertis said this study also links two formerly unrelated areas of biology. A cell’s cytoplasm is filled with internal membranes that shuttle proteins to their final destinations. Cells in tissues communicate with their neighbors by receiving external signals called growth factors. This new research links the cell biology of membrane trafficking and the interpretation of the signals that control cell proliferation.
“Protein degradation is a very important part of the life of a cell. About 10 percent of the genes in the genome are dedicated to protein degradation,” De Robertis said. “We now know that Wnt causes an enzyme that degrades proteins to be sequestered and because of that becomes a regulator of cellular protein stability.”
De Robertis characterized this finding as “very unexpected.”
“No one thought you could have cell signaling through sequestration of an enzyme inside a membrane organelle like these multivesicular bodies,” he said. This is because the GSK3 enzyme is normally found everywhere in the cell, but becomes tightly bound to the internal side of membrane receptors when the Wnt signal is received.
The study was funded by the National Institutes of Health, the Howard Hughes Medical Institute and the Norman Sprague Endowment for Molecular Oncology.
UCLA’s Jonsson Comprehensive Cancer Center has more than 240 researchers and clinicians engaged in disease research, prevention, detection, control, treatment and education. One of the nation’s largest comprehensive cancer centers, the Jonsson Center is dedicated to promoting research and translating basic science into leading-edge clinical studies. In July 2010, the center was named among the top 10 cancer centers nationwide by U.S. News & World Report, a ranking it has held for 10 of the last 11 years.